Volume 3.13 | Apr 9

Cancer Stem Cell News 3.13 April 9, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
HMMR Maintains the Stemness and Tumorigenicity of Glioblastoma Stem-Like Cells
Researchers report that the hyaluronan-mediated motility receptor HMMR is highly expressed in glioblastoma tumors where it supports the self-renewal and tumorigenic potential of glioblastoma stem cells. [Cancer Res] Abstract
[Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.
 
PUBLICATIONS (Ranked by impact factor of the journal)
Endothelial Cell-Secreted EGF Induces Epithelial to Mesenchymal Transition and Endows Head and Neck Cancer Cells with Stem-Like Phenotype
Scientists report that squamous cell carcinoma (SCC) cells within the perivascular niche have undergone epithelial to mesenchymal transition (EMT) in a primary human SCC of a patient that developed distant metastases. Endothelial cell-secreted EGF induced EMT of human SCC cells in vitro and also induced acquisition of a stem-like phenotype. [Cancer Res] Abstract

Oncogenic miR-20a and miR-106a Enhance the Invasiveness of Human Glioma Stem Cells by Directly Targeting TIMP-2
Scientists demonstrated that two functionally related microRNAs, miR-20a and -106a, were capable of enhancing the invasiveness of CD133+ glioma stem cells isolated from both glioblastoma cell line U87 and primary human glioma specimens. [Oncogene] Abstract

Hif-1a and Hif-2a Differentially Regulate Notch Signaling through Competitive Interaction with the Intracellular Domain of Notch Receptors in Glioma Stem Cells
Researchers showed that hypoxia promoted proliferation, self-renewal and inhibited the conversion of glioma stem cells into INP-like cells through activating Notch signaling. [Cancer Lett] Abstract

Suppressive Expression of CD274 Increases Tumorigenesis and Cancer Stem Cell Phenotypes in Cholangiocarcinoma
Researchers demonstrated that CD274, known as an immunomodulatory ligand, has suppressive effects on cancer stem cell-related phenotypes of cholangiocarcinoma. [Cancer Sci] Abstract

The Acquisition of Cancer Stem Cell-Like Properties and Neoplastic Transformation of Human Keratinocytes Induced by Arsenite Involves Epigenetic Silencing of Let-7c via Ras/NF-?B
Scientists report that there are decreased levels of let-7a, let-7b, and let-7c in human keratinocyte HaCaT cells during malignant transformation induced by a low concentration of arsenite. [Toxicol Lett] Abstract

Triptolide-Induced In Vitro and In Vivo Cytotoxicity in Human Breast Cancer Stem Cells and Primary Breast Cancer Cells
Scientists investigated the potential efficacy of the Chinese herbal extract triptolide for the treatment of human breast cancer by measuring the triptolide-induced cytotoxicity in cultures of human primary breast cancer cells and breast cancer stem cells in vitro and in vivo. [Oncol Rep] Abstract

MicroRNA Expression Pattern Modulates Temozolomide Response in GBM Tumors with Cancer Stem Cells
Researchers evaluated the microRNA expression patterns associated with chemoresistance that is dependent on the cancer stem cells status in glioblastoma multiforme (GBM) tumors to identify therapeutic biomarkers. [Cell Mol Neurobiol] Abstract

Triptolide Synergistically Enhances Temozolomide-Induced Apoptosis and Potentiates Inhibition of NF-?B Signaling in Glioma Initiating Cells
Scientists found that glioma-initiating cell-1 cells were resistant to temozolomide (TMZ), with the expected IC50 of 705.7 µmol/L. Co-treatment with triptolide (TPL) yielded a more than three-fold dose reduction of TMZ. TPL significantly increased the percentage of apoptotic cells and suppressed the tumor sphere formation when combined with TMZ. [Am J Chin Med] Abstract

MammoCult™: Most Published Mammosphere & Tumorsphere Culture Medium (Commercially Available) - FREE Sample Request
 
REVIEWS
Glioma Stem Cells: Turpis Omen in Nomen? (The Evil in the Name?)
The authors review key findings on somatic, neural and solid tumor stem cells (SCs), also taking into account the emerging phenomenon of phenotypic SC plasticity. [J Intern Med] Abstract

Nanomaterials for Targeted Drug Delivery to Cancer Stem Cells
Understanding the functional biology of cancer stem cells – especially the signaling pathways that are involved in their self-renewal mechanisms – is crucial for discovering new forms of treatment. In this review, the authors highlight current and future prospects for potential cancer therapies based on the use of nano-sized materials. [Drug Metab Rev] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Attend the 9th Annual World Stem Cells & Regenerative Medicine Congress in London!
 
SCIENCE NEWS
Verastem Presents Data on Cancer Stem Cell-Targeting Agents
Verastem, Inc. presented data in support of its programs targeting cancer stem cells through inhibition of the focal adhesion kinase and PI3K/mTOR signaling pathways. [Press release from Verastem, Inc. discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2014, San Diego]
Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
INDUSTRY NEWS
Mahendra Rao Joins The New York Stem Cell Foundation Research Institute
Dr. Mahendra Rao, who has directed the Center for Regenerative Medicine at the National Institutes of Health since 2010, will join The New York Stem Cell Foundation (NYSCF) Research Institute as its Vice President for Regenerative Medicine, a newly created position, Susan Solomon, NYSCF Chief Executive Officer, announced. [The New York Stem Cell Foundation] Press Release

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data
Pharmacyclics, Inc. announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration, based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, who had received at least one prior therapy. [Pharmacyclics, Inc.] Press Release
 
POLICY NEWS
NIH Stem-Cell Program Closes
Stem-cell researchers at the US National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agency’s Center for Regenerative Medicine. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW FEBS-EMBO 2014 Conference
August 30 – September 4, 2014
Paris, France

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Associate – Extracellular Microenvironment in Cancer (Institute of Translational Medicine, University of Liverpool)

NEW MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Faculty Positions – Cancer Research (Stephenson Cancer Center at the University of Oklahoma)

Postdoctoral Position – Cancer Biology (IRCAN)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Tenure-Track Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center)

Postdoctoral Position – Glioblastoma, Oncolytic Virus and Cell Signaling (Ohio State University)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Faculty Position – Cancer Biology and Evolution (Moffitt Cancer Center & Research Institute)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us